ABSTRACT
PURPOSE: The efficacy of i.âv. thrombolysis in acute stroke with high clot burden is limited. Successful recanalization is very unlikely if the thrombus length exceeds 7âmm. Thus this retrospective controlled study evaluated the efficacy and safety of neurothrombectomy in the treatment of acute embolic stroke in patients selected by a thrombus length of ≥â8âmm using the stent retriever Trevo(®) device. MATERIALS AND METHODS: 40 patients with acute occlusion of the anterior intracranial arteries with a thrombus length of ≥â8âmm were treated with neurothrombectomy. We compared the outcome with a historical cohort of 42 patients with a thrombus length of ≥â8âmm that received i.âv. thrombolysis only. Clinical outcome was assessed by modified Rankin scale in both groups at discharge and on day 90. RESULTS: Patients did not differ in age, mRS on admission, thrombus length or time from symptom onset to i.âv. thrombolysis, but the thrombectomy group had higher NIHSS on admission. Successful recanalization was achieved in 33/40 patients (83â%) with neurothrombectomy. 15 patients received i.âv. thrombolysis prior to neurothrombectomy. Median mRS at discharge was 3.5 (1.25â-â5) vs. 5 (4â-â6; pâ<â0.01) and on day 90 3 (1â-â4) vs. 5 (4â-â6; pâ<â0.01). Symptomatic hemorrhage occurred in 3 vs. 7 patients. 3 vs. 17 patients died within 90 days (thrombectomy vs. control each). There were only a few intervention-related complications. CONCLUSION: Thrombectomy in acute stroke with high clot burden using the Trevo(®) device has a low risk and improved clinical outcome compared to i.âv. thrombolysis alone. Treatment selection by a clot length of ≥â8âmm might be a powerful approach to improve the outcome of mechanical thrombectomy. KEY POINTS: â¢âClot length of ≥â8âmm might be a valuable criterion for indicating neurothrombectomy. â¢âThrombolysis only in high clot burden is associated with poor clinical outcome. â¢âThrombectomy using the Trevo(®) stent retriever is safe and effective.
Subject(s)
Fibrinolytic Agents/administration & dosage , Intracranial Embolism/therapy , Mechanical Thrombolysis/instrumentation , Stroke/therapy , Thrombolytic Therapy/methods , Adult , Aged , Aged, 80 and over , Fibrinolytic Agents/adverse effects , Fibrinolytic Agents/therapeutic use , Humans , Injections, Intravenous , Mechanical Thrombolysis/adverse effects , Mechanical Thrombolysis/methods , Middle Aged , Postoperative Hemorrhage/etiology , Postoperative Hemorrhage/prevention & control , Prosthesis Design , Retrospective Studies , Severity of Illness Index , Stents , Thrombolytic Therapy/adverse effects , Treatment Outcome , Young AdultABSTRACT
The neuroprotective effect of oxygen after acute stroke in rats has been shown previously. However, the question of optimal dosing still remains unanswered. Thus, we investigated the use of oxygen at different concentrations by either normobaric oxygenation (NBO) or hyperbaric oxygenation (HBO) at different pressures in a model of transient ischemia/reperfusion in rats. Animals underwent 90 min of middle cerebral artery occlusion (MCAO) followed by 90 min of reperfusion before oxygen treatment. Oxygen was applied either by NBO (100% O(2); 1.0 absolute atmosphere, ATA) or HBO (100% O(2); 1.5, 2.0, 2.5 or 3.0 ATA) for 1 h. Primary endpoints were infarct volume and clinical outcome measured 24 h and 7 days following the MCAO. A statistically significant and long-lasting reduction in infarct volume was seen in the HBO 2.5 ATA and 3.0 ATA groups over a period of 7 days. The reduced infarct volume was accompanied with a statistically significant improvement in clinical outcome in the high-dose oxygen-treated groups. The presented data indicate that oxygen is a highly neuroprotective molecule in transient focal cerebral ischemia in rats, when applied early and at high doses. The effect is dose dependent and shows a superiority of HBO over NBO, when the primary endpoints infarct volume reduction and clinical outcome are analyzed. These data are important for the development of new acute stroke treatment studies in humans.